GeoffroyPineau-Valencienne

Partner

Paris + 33.1.56.59.39.39

Connect:

Share

Geoffroy Pineau-Valencienne has extensive experience in venture capital, private equity, M&A, and capital markets transactions. He represents a large number of private and public companies at every stage of development, from entrepreneurial start-ups to global corporations, particularly in the life sciences and technology fields, as well as financial and industrial investors.

He also represents, on a regular basis, tech and biopharmaceutical companies in transactional matters in relation to joint ventures and strategic partnerings, product development, distribution, and licensing agreements.

Geoffroy's recent experience includes representation of technology and life sciences companies such as Amoéba, Amolyt Pharma, Cellectis, Criteo, Enertime, Eurobio, Genticel, Inotrem, Mathym, Mauna Kea Technologies, Orega Biotech, Orphélia Pharma, Talend, Trace One, and Urban Canopée. His recent investor-side representations include: Alven, Andera, Balderton, BioMed, Bpifrance, CEA Investissement, CITA, Elaia, Fa-Dièse, Havenrock, HI Inov, Hil-Invest, Idinvest, Novo Holdings, Partech, Regenxbio, Riverside, Serena, Seventure, Supernova, Ventech, Wellington, and Western Digital.

Illustrative examples of the transactions in which Geoffroy acted as lead lawyer include IPOs and follow-on offerings (Amoéba, Genticel, and Enertime on the main or Growth market of Euronext Paris and Cellectis and Talend on Nasdaq), private and public M&A transactions (the acquisition of Pipplet by ETS Global; the sales of Alizé Pharma to Millendo, Mathym to Baikowski, Endocontrol to Canady Life Sciences, and SoCloz to Savoye; and the reverse merger of Genticel to Genkyotex), and venture capital financings, either on issuer- or investor-side (in connection with the financing rounds of Amolyt Pharma, Alédia, Inotrem, Mutabilis, Lendix, UpMem, Urban Canopée, UroMems, and TriCares).

Experience

  • Amolyt Pharma enters into definitive agreement to be acquired by AstraZenecaJones Day is advising Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, in its $1.05 billion acquisition by AstraZeneca.
  • Bpifrance, INCO Ventures and SEB Alliance invest in VulkamJones Day advised Bpifrance, INCO Ventures and SEB Alliance in the €34 million financing of Vulkam, a deeptech company whose mission is to revolutionize metallurgy through the industrial development of amorphous metals.
  • Cortec Group sells Chauvet & Sons to Court Square Capital PartnersJones Day advised Cortec Group in the sale of its Chauvet & Sons platform to Court Square Capital Partners.
  • Bpifrance (SPI fund) participates in €61 million Series C financing of CorWave, together with other investorsJones Day advised Bpifrance (SPI fund) in connection with the €61 million Series C financing of CorWave, a high-tech medical devices company that has developed a next-generation heart pump based on a breakthrough technology, the wave membrane pump, together with other investors.
  • DIC acquires photoresist polymers manufacturer PCAS CanadaJones Day advised DIC Corporation, a Japanese chemicals group operating globally in over 60 countries, in connection with its acquisition of Quebec-based PCAS Canada Inc., a company that manufactures and sells polymers used in photoresists for semiconductor photolithography, from PCAS S.A., a French company.
  • Bpifrance (SPI fund), GoCapital and NCI invest in ExpliseatJones Day advised Bpifrance (SPI fund), GoCapital and NCI in the €17 million Series B financing of Expliseat, a company specializing in the design and manufacture of innovative lightweight seat technology.
  • Amolyt Pharma enters research agreement and licensing option with XOMAJones Day advised Amolyt Pharma, a global company specialized in developing innovative therapies for rare endocrine and related diseases, in the research agreement and licensing option with XOMA Corporation for the pre-clinical evaluation of a select set of monoclonal antibodies that arose from XOMA’s legacy discovery efforts as potential treatments for primary hyperparathyroidism and humoral hypercalcemia of malignancy. Amolyt has the option to license one or more of these candidates from XOMA for further clinical development worldwide.
  • Amolyt Pharma raises $138 million in Series C financingJones Day advised Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, in connection with its $138 million Series C financing led by Sofinnova Partners and co-led by Intermediate Capital Group (ICG), along with Tekla Capital Investment LLC, and CTI Life Sciences as well as existing investors, including, Andera Partners, Kurma, Bpifrance (Innobio), Sectoral, and Pontifax.
  • Eurobio Scientific acquires GenDxJones Day advised Eurobio Scientific SA in the acquisition and financing of the Dutch company Genome Diagnostics BV (GenDx) from its founder and its shareholders for €135 million (net of adjusted cash).
  • Omnes Capital leads $10 million financing round of WhiteLab GenomicsJones Day represented Omnes Capital as a lead investor in connection with the $10 million financing round of WhiteLab Genomics, a Y-Combinator backed AI-powered predictive software simulation platform for the design of gene and cell therapies.
  • Masteos raises €40 million in Series A financing roundJones Day advised Masteos SAS, a French tech company that provides advice and support services in real estate acquisition, renovation, and rental investment, in connection with its €40 million Series A financing round led by DST Global Partners with Daphni also participating.
  • CTI Life Sciences Fund, Panacea Venture, and 3B Future Health Fund co-lead $42 million Series A funding of Domain TherapeuticsJones Day represented CTI Life Sciences Fund, Panacea Venture, and 3B Future Health Fund as co-leaders in the $42 million Series A financing round of Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, along with other investors.
  • Fortino Capital acquires majority stake in BonitasoftJones Day advised Fortino Capital Partners NV in acquiring a majority stake in Bonitasoft, a leading software company active in the field of Digital Process Automation and Intelligent Business Process Management, from former investors.
  • Pretto (Finspot) raises €30 million in Series B financing roundJones Day advised Pretto (Finspot), a French-based company engaged in online mortgage brokerage, in connection with its €30 million Series B round of financing led by Serena Capital, Eurazeo IM, and Orange Ventures.
  • Waga Energy completes €110 million IPO on Euronext in Paris, with green shoe optionJones Day advised Waga Energy, a French company specialized in the recovery of landfill gas as biomethane, in connection with its €110 million initial public offering of Ordinary Shares on the regulated market of Euronext in Paris with an over-allotment option up to €123 million.
  • Amolyt Pharma raises $80 million in Series B financing roundJones Day advised Amolyt Pharma, a French based company engaged in the research and development of new therapeutic strategies for the treatment of rare endocrine and metabolic diseases, in connection with its $80 million Series B round of financing co-led by Sectoral Asset Management and Andera Partners.
  • Bpifrance sells interests in HalioDx to Veracyte, Inc.Jones Day represented Bpifrance in the sale of its interests in HalioDx, a French private biotech company specialized in immune-based diagnostic products and services, as part of the €260 million sale of HalioDx to Veracyte, Inc., a U.S. global genomic diagnostics company listed on the Nasdaq.
  • Deutsche Bank and Société Générale underwrite €165 million SPAC IPO by DEE TechJones Day represented Deutsche Bank, as sole global coordinator and joint bookrunner, and Société Générale, as joint bookrunner, in connection with the €165 million initial public offering by DEE Tech, the first ever French SPAC in the tech sector, which will be listed on the Professional Segment of the regulated market of Euronext Paris.
  • Omnes Capital, IRDI Capital Investissement, Swen Capital Partners, and UL Holding S.A participate in €8.5 million investment in PeopleSpheresJones Day represented Omnes Capital, IRDI Capital Investissement, Swen Capital Partners, and UL Holding S.A. in connection with their participation in a €8.5 million investment in PeopleSpheres, a Paris, France-based developer of a SAAS solution for HR.
  • Cellectis establishes at-the-market (ATM) program for up to US$125 million on NasdaqJones Day assisted Cellectis SA in connection with the implementation of an at-the-market (ATM) program for up to US$125 million on Nasdaq and the subsequent first draw down of US$47 million under the program.
    • View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.